Trial Profile
Feasibility study of Carboplatin plus Pemetrexed in patients with recurrent and postoperative non-small cell lung cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 Jan 2019
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 28 Jan 2014 Planned End Date changed from 1 Apr 2012 to 30 Jun 2015 as reported by University Hospital Medical Information Network - Japan record.
- 19 Jan 2011 New trial record